指南与共识心脑血管急症消化、代谢与肾脏急症

专业协会关于PCSK9抑制剂处方的共识声明

[Consensus statement of professional associations on prescribing of PCSK9-inhibitors].
指南 / 共识 · Vnitr Lek · 2019-01-01
一句话结论PCSK9抑制剂用于家族性高胆固醇血症(LDL-C≥4.0 mmol/l)或心血管病二级预防(LDL-C≥3.0 mmol/l)且已在最大耐受高强度降脂治疗下仍未达标者,需在指定中心处方。

该共识声明由专业协会发布,阐述PCSK9抑制剂(PCSK9i)的处方指征与报销条件。PCSK9i为皮下注射、每2或4周一次的生物制剂,不替代现有降脂药,而是扩展治疗谱。适应证包括高胆固醇血症和混合型血脂异常,以及心血管病二级预防。报销条件为:在最大耐受高强度降脂治疗(阿托伐他汀40-80 mg或瑞舒伐他汀20-40 mg+依折麦布)下,家族性高胆固醇血症LDL-C≥4.0 mmol/l或二级预防LDL-C≥3.0 mmol/l,且在指定中心处方。他汀不耐受本身不是PCSK9i的适应证。

要点

  • PCSK9i皮下注射,每2周或每4周一次,不替代现有降脂药,用于标准治疗未达标者。
  • 报销条件:家族性高胆固醇血症LDL-C≥4.0 mmol/l,或心血管病二级预防LDL-C≥3.0 mmol/l。
  • 上述LDL-C水平须在最大耐受高强度降脂治疗下测得:阿托伐他汀40-80 mg或瑞舒伐他汀20-40 mg+依折麦布。
  • 他汀不耐受定义为至少连续两种他汀不耐受并导致停药;他汀不耐受本身不是PCSK9i的适应证。
  • PCSK9i治疗在指定中心提供,中心列表见附件及www.interna-cz.eu、www.kardio-cz.cz、www.athero.cz。

适用人群与场景

  • 高胆固醇血症和混合型血脂异常患者
  • 心血管病二级预防患者
  • 标准降脂治疗未达满意目标值者
  • 不能使用标准治疗者

诊断标准与关键阈值

  • 报销条件(简化):家族性高胆固醇血症LDL-C≥4.0 mmol/l,须在最大耐受高强度降脂治疗下测得。
  • 报销条件(简化):心血管病二级预防LDL-C≥3.0 mmol/l,须在最大耐受高强度降脂治疗下测得。
  • 高强度降脂治疗定义为阿托伐他汀40-80 mg或瑞舒伐他汀20-40 mg+依折麦布。
  • 已证实对上述两种他汀均不耐受者,须使用最大耐受剂量他汀联合另一种降脂药(依折麦布)。
  • 他汀不耐受定义为至少连续两种他汀不耐受并导致停药。

处置流程与药物剂量

  • PCSK9i通过皮下注射给药,每2周或每4周一次。
  • PCSK9i不替代现有降脂药,而是扩展治疗谱。
  • 治疗在指定中心提供,中心列表见附件及www.interna-cz.eu、www.kardio-cz.cz、www.athero.cz。
  • 支付标准必须始终遵守;例外情况下可请医疗官员批准。

研究设计与关键结果

  • 制定机构:专业协会;方法:共识声明;证据分级体系:原文未报告。

证据类型、等级与局限

  • 证据类型:共识声明。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • PCSK9i处方须符合报销标准:家族性高胆固醇血症LDL-C≥4.0 mmol/l或二级预防LDL-C≥3.0 mmol/l,且在最大耐受高强度降脂治疗下。
  • 他汀不耐受本身不是PCSK9i的适应证,须同时满足LDL-C支付标准。
  • PCSK9i须在指定中心处方。

指南或共识出处

  • 专业协会关于PCSK9抑制剂处方的共识声明(Vnitr Lek)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

A new class of drugs known as PCSK9 inhibitors (PCSK9i) provide biological treatment for hypercholesterolemia. These drugs are administered using a subcutaneous injection once in two or four weeks. PCSK9i are not a replacement of the existing hypolipidemics, they just expand the therapeutic spectrum for the critically ill and those who cannot use the standard therapy and do not reach satisfactory target values. There are essentially two indications: (1) hypercholesterolemie and mixed dyslipidemia and (2) secondary prevention of cardiovascular diseases (CVD). Statin intolerance is not the only indication for treatment. However as its presence sometimes plays an essential role as to choosing the treatment, it will be also discussed in the paragraph on reimbursement conditions. Reimbursement conditions (very simplified): the treatment will be provided at selected centres. A list of the centres is included in an annexe to this article. You will find it also on www.interna-cz.eu, on www.kardio-cz.cz and www.athero.cz. The indicative concentration of LDL-cholesterol (LDL-C) from which on PCSK9i can be prescribed as covered from the public health insurance, is the following: (1) familial hypercholesterolemia 4.0 mmol/l, (2) for secondary prevention CVD 3.0 mmol/l - Please note: the presented LDL-C level is one reached under maximum (tolerated) high intensity hypo-lipidemic therapy. High intensity hypolipidemic therapy is defined as atorvastatin 40-80 mg or rosuvastatin 20-40 mg + ezetimibe. In the case of demonstrated intolerance of both the mentioned statins the patient has to be treated with a maximum tolerated dose of statins, in combination with another hypolipidemic drug (ezetimibe). Statin intolerance is defined as intolerance of at least two successive statins, which results in their discontinuation. Statin intolerance alone is not the indication for PCSK9i treatment! The payment criteria must always be complied with. A medical officer can of course be asked to approve such treatment in exceptional cases. Key words: alirocumab - PCSK9 inhibitors centers - center therapy - evolocumab - familial hypercholesterolemia - proprotein konvertase subtilisin kexin 9 inhibitors (PCSK9i) - secondary prevention - statins intolerance.

来源:Vnitr Lek,查看原文。版权归原作者所有。

参考来源

  1. Češka R, Táborský M, Vrablík M, et al. [Consensus statement of professional associations on prescribing of PCSK9-inhibitors]. Vnitr Lek. 2019. PMID: 30704246

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。